BioSpace News Archive

Vor Bio announced that preclinical and clinical data supporting the Company’s novel platform and approach for treating acute myeloid leukemia, will be presented at the 65th American Society of Hematology Annual Meeting & Exposition, being held from December 9-12, 2023, in San Diego, CA.

Endologix LLC announced results from a pooled analysis of DETOUR1 and DETOUR2 Studies evaluating Percutaneous Transmural Arterial Bypass with the DETOUR System.

Scholar Rock today announced that management will participate in the following upcoming investor conferences.

Prominent contract research organization, Purpose Life Sciences (PLS) is set to launch a groundbreaking Phase III clinical trial in conjunction with Dr. Gilmar Reis of Card Research, an expansive medical clinic network based in Brazil.

Allogene Therapeutics, Inc. announced that it will have two poster presentations focused on the importance of lymphodepletion in allogeneic cell therapy at the 65th Annual Meeting of the American Society of Hematology taking place December 9-12, 2023 in San Diego, CA.

ORIC Pharmaceuticals, Inc. announced a poster presentation on the initial Phase 1b clinical data for ORIC-533 in patients with relapsed/refractory multiple myeloma at the 65th American Society of Hematology Annual Meeting to be held December 9-12, 2023, in San Diego, CA.

Jasper Therapeutics, Inc. announced that positive final results from the Phase 1 study of briquilimab in combination with fludarabine and low-dose irradiation conditioning in older adults with AML in complete remission or myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplant will be presented during an oral session at the ASH 2023 Annual Meeting & Exposition, being held December 9-12, 2023, in San Diego, CA.

Gracell Biotechnologies Inc. announced that the updated results from its clinical investigator-initiated trial of GC012F for treatment of newly diagnosed multiple myeloma will be presented as an oral presentation at the 65th American Society of Hematology Annual Meeting & Exposition taking place in San Diego, California and online during December 9-12, 2023.

Cogent Biosciences, Inc., a biotechnology company focused on developing precision therapies for genetically defined diseases, reported recent business highlights and financial results for the third quarter ended September 30, 2023.

Vetigenics announces that the first canine patient with stage 4 oral melanoma has received his first dose of Vetigenics’ fully canine anti-CTLA4 monoclonal antibody following standard of care radiation therapy.